Korro Bio, Inc. short interest in 2022
In 2022, Korro Bio, Inc.'s disclosed short interest ran from 9.44% of shares outstanding on 14 Jan 2022 to 1.20% on 30 Dec 2022, a change of -8.24 percentage points. The year's high was 9.44% on 14 Jan 2022 and its low 1.20% on 30 Dec 2022, averaging 3.35% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.28 days on 14 Jan 2022. Full history: Korro Bio, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 9.44% (14 Jan 2022)
- End of year
- 1.20% (30 Dec 2022)
- Change
- -8.24 pp
- High
- 9.44% (14 Jan 2022)
- Low
- 1.20% (30 Dec 2022)
- Average
- 3.35%
- Highest days to cover
- 15.28 (14 Jan 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 9.44% | 15.28 | |
| 31 Jan 2022 | 6.49% | 8.42 | |
| 15 Feb 2022 | 3.84% | 6.31 | |
| 28 Feb 2022 | 3.14% | 4.04 | |
| 15 Mar 2022 | 4.03% | 3.87 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 4.06% | 4.59 | |
| 14 Apr 2022 | 4.45% | 1.61 | |
| 29 Apr 2022 | 5.00% | 1.19 | |
| 13 May 2022 | 5.86% | 2.55 | 10-Q filed, results (8-K) |
| 31 May 2022 | 5.06% | 3.03 | |
| 15 Jun 2022 | 4.41% | 3.07 | |
| 30 Jun 2022 | 3.04% | 1.26 | |
| 15 Jul 2022 | 2.52% | 1.06 | |
| 29 Jul 2022 | 2.34% | 3.82 | |
| 15 Aug 2022 | 2.13% | 3.02 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 2.06% | 5.22 | |
| 15 Sep 2022 | 1.96% | 5.47 | |
| 30 Sep 2022 | 1.97% | 6.83 | |
| 14 Oct 2022 | 1.77% | 9.37 | |
| 31 Oct 2022 | 1.56% | 8.45 | |
| 15 Nov 2022 | 1.43% | 3.64 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 1.41% | 5.39 | |
| 15 Dec 2022 | 1.26% | 6.28 | |
| 30 Dec 2022 | 1.20% | 1.00 |
See also: Korro Bio, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.